Eli Lilly and Company News - August 31, 2026
Eli Lilly commits $25B to deals, diversifying beyond obesity drugs
Eli Lilly CEO David Ricks outlined a strategy to secure growth into the 2030s during a CNBC interview. The company committed over $25 billion to more than 12...
Lilly's Zepbound and Taltz Combo Shows Sustained Efficacy in Psoriatic Disease
Eli Lilly announced positive 52-week results from two Phase 3b trials. The trials showed its weight-loss drug Zepbound, combined with arthritis treatment...
Eli Lilly buys Merida for $2.88B, leveraging obesity profits for autoimmune growth
Eli Lilly entered a definitive agreement to acquire Merida Biosciences for up to $2.88 billion. The deal includes an upfront cash payment plus additional...